-+ 0.00%
-+ 0.00%
-+ 0.00%

Galmed, Tissue Dynamics say Aramchol combo cuts fibrosis about 4-fold in human cardiac organoid study

PUBT·06/02/2026 11:31:24
Listen to the news
Galmed, Tissue Dynamics say Aramchol combo cuts fibrosis about 4-fold in human cardiac organoid study
  • Galmed disclosed preclinical study results on June 2, 2026, supporting Aramchol Meglumine development for cardiac fibrosis.
  • Human cardiac organoid work indicated the drug combination lowered fibrotic burden while preserving heart muscle structure and metabolic function.
  • Findings point to a human-specific metabolic pathway not captured in conventional animal models, strengthening the rationale for clinical translation.
  • A new patent application was filed, with preparations underway for future IND-enabling work toward clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO73597) on June 02, 2026, and is solely responsible for the information contained therein.